Anavex Life Sciences (AVXL) Other Non-Current Liabilities (2013)
Anavex Life Sciences recorded quarterly Other Non-Current Liabilities of $904000.0 in Q3 2013.
Anavex Life Sciences' Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $904000.0 for Q3 2013.
- In Q3 2013, Other Non-Current Liabilities changed N/A year-over-year to $904000.0; the TTM figure through Sep 2013 stood at $904000.0 (changed N/A YoY), while the FY2013 annual figure was $904000.0, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $904000.0 for Q3 2013 at Anavex Life Sciences.
- In the past five years, Other Non-Current Liabilities ranged from a high of $904000.0 in Q3 2013 to a low of $904000.0 in Q3 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 904,000.00 |